Revvity, Inc. (RVTY)
| Market Cap | 10.10B -21.7% |
| Revenue (ttm) | 2.86B +3.7% |
| Net Income | 241.20M -10.8% |
| EPS | 2.07 -5.8% |
| Shares Out | 111.80M |
| PE Ratio | 42.65 |
| Forward PE | 16.25 |
| Dividend | $0.28 (0.31%) |
| Ex-Dividend Date | Apr 17, 2026 |
| Volume | 335,617 |
| Open | 91.44 |
| Previous Close | 87.79 |
| Day's Range | 89.65 - 92.99 |
| 52-Week Range | 81.36 - 118.30 |
| Beta | 1.13 |
| Analysts | Buy |
| Price Target | 111.87 (+23.85%) |
| Earnings Date | Apr 27, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $111.87, which is an increase of 23.85% from the latest price.
News
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday,...
Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high...
Revvity Analysts Boost Their Forecasts Following Better-Than-Expected Q4 Results
Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers
Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.
Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter
Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics bu...
Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8...
Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads.
Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.
Revvity says it will exceed 2025 profit forecast range
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and dia...
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 20...
Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly's high-quality predictive models by making L...
Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and Chief Executiv...
Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals pl...
Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation ...
Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that sup...
Revvity Analysts Increase Their Forecasts After Q3 Earnings
Revvity, Inc. (NYSE:RVTY) announced mixed third-quarter 2025 financial results on Monday.
Revvity lifts annual profit forecast on renewed demand in diagnostics unit
Medical equipment maker Revvity on Monday raised its annual profit forecast and beat third-quarter estimates on improving demand for its testing kits in the diagnostics unit.
Revvity Announces Financial Results for the Third Quarter of 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as ...
Revvity Showcases Progress with Purpose in 2025 Impact Report
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company's sustainability, social and governance strategy, initiat...
Revvity to Hold Earnings Call on Monday, October 27, 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company...
Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with s...
Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis
WALTHAM, Mass.--(BUSINESS WIRE)--Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provi...
Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established ...
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Resear...
Revvity Launches Innovative Reagent Technology to Accelerate Development of Next-Generation Targeted Therapeutics
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSen...